



## **Immatics Press Release**

### **Immatics Appoints Thomas Ulmer as Chief Financial Officer**

**Tuebingen, Germany and Houston, Texas, January 17, 2018** – Immatics, a leading company in the field of cancer immunotherapy, today announced the appointment of Thomas Ulmer as Chief Financial Officer (CFO), effective April 1st, 2018.

Thomas joins Immatics from the Merck Group, where he is currently Chief Financial Officer of the Allergopharma Business Unit. Thomas began his professional career with Merck in 2004 and has held a number of roles, including Head of Business Planning & Analysis and previously Head of Planning, Forecasting & Resource Allocation for the Merck Group. He has also been Chief Financial Officer for Australia/ New Zealand and Financial Controller for Merck’s global generics business. Thomas is a Certified Practising Accountant and holds an MBA.

Peter Chambré, Chairman of Immatics, said: “We are delighted that Thomas is joining Immatics as our CFO. He will bring his exceptional financial expertise and experience to Immatics at a key time in the Company’s development. Building on our world-leading T-cell receptor (TCR) and target discovery platform XPRESIDENT®, we currently have a number of adoptive cellular therapy clinical trials underway, with more expected to commence in 2018. We are also progressing our pipeline of proprietary Bispecific TCR candidates. As we develop Immatics for the future, Thomas will be a key member of the Management team executing our strategy and advancing our broad portfolio of immunotherapies for the treatment of cancer.”

Thomas Ulmer, Chief Financial Officer of Immatics, said: “I am thrilled to be joining Immatics at this exciting time in its development, with several clinical trials of Immatics’ adoptive cellular therapies underway and plans in place to grow the pipeline in the coming years. Immatics has unique and impressive proprietary technologies and I look



forward to contributing to the future of the Company, as it sets about its goal to change the course of cancer for patients.”

### **About Immatics**

Immatics is a clinical-stage biopharmaceutical company spearheading the development of advanced immunotherapies that are active against multiple cancer indications. Based in Tuebingen, Germany, and Houston, Texas, the company has recognized that novel, better and safer targets are the key to developing future cancer immunotherapies. Immatics has revolutionized the identification and qualification of novel, proprietary and tumor-specific peptide antigens (TUMAPs) by developing its world-leading T-cell receptor (TCR) and target discovery platform XPRESIDENT®. TUMAPs significantly expand the target space for immune-oncology as they are not limited to surface proteins, which are the targets of classical antibodies or CAR-T therapies. Immatics believes that, by using its proprietary expertise, it can unlock the significant potential of immune-oncology drugs, such as adoptive cellular therapies, biologicals and vaccines to improve the treatment of a wide range of cancers.

Immatics’ pipeline includes several bispecific TCR molecules and T-cell therapy programs, including ACTolog® and ACTengine® which are developed in collaboration through Immatics US with MD Anderson, and co-funded by the Cancer Prevention and Research Institute of Texas (CPRIT). By using its world-leading target and TCR discovery expertise, Immatics aims to deliver safer, best-in-class immunotherapies to cancer patients with high medical need in multiple indications.

For regular updates about Immatics, visit [www.immatics.com](http://www.immatics.com).

### **Media contact:**

Dr. Nikola Wiegeler

Phone : +49 7071 5397 110

[media@immatics.com](mailto:media@immatics.com)